Department of Ophthalmology, Medical Faculty, Karadeniz Technical University, Trabzon, Turkey.
Lasers Med Sci. 2021 Jul;36(5):981-988. doi: 10.1007/s10103-020-03129-5. Epub 2020 Aug 19.
Central serous chorioretinopathy (CSC) is a disease characterized by a well-defined serous detachment of the neurosensory retina. Therapeutic options in chronic cases are limited, and side effects can result in a limited response. The aim of this article is to assess the efficacy of subthreshold micropulse laser therapy in patients with chronic central serous chorioretinopathy. The study included 20 eyes of 19 patients who had a history of chronic or chronic recurrent CSC and who underwent subthreshold micropulse laser therapy between January 2015 and June 2018. Twenty eyes of 19 patients with a mean age of 48.9 ± 9.40 years were included. The mean visual acuity was 0.24 ± 0.28 logMAR before laser, 0.19 ± 0.25 logMAR 3 months after laser, and 0.18 ± 0.27 logMAR after 6 months. A statistically significant difference was determined in terms of visual acuity before and after treatment (p = 0.0001). The mean central retinal thickness was 308.10 ± 95.25 μm before laser, 233.65 ± 81.17 μm 3 months after laser, and 203.88 ± 72.79 μm at 6 months. A statistically significant relationship was present between visual acuity and the duration of disease (p = 0.001), between visual acuity and the outer nuclear layer thickness (p = 0.005), and between the outer nuclear layer thickness and the duration of disease in chronic cases (p = 0.008). There was no evidence of retinal pigment epithelium or retinal damage on optical coherence tomography or fundus autofluorescence secondary to subthreshold micropulse laser therapy. Visual acuity appears to be more associated with the duration of disease and with changes in the outer nuclear layer thickness in chronic CSC. Subthreshold micropulse laser therapy seems to be effective at treating chronic CSC, while it increases success during early period of the disease before the development of permanent retinal damage.
中心性浆液性脉络膜视网膜病变（CSC）是一种以神经感觉视网膜明显浆液性脱离为特征的疾病。慢性病例的治疗选择有限，且副作用可能导致反应受限。本文旨在评估阈下微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变患者的疗效。该研究纳入了 2015 年 1 月至 2018 年 6 月期间接受阈下微脉冲激光治疗的 19 例慢性或慢性复发性 CSC 患者的 20 只眼。纳入的 19 例患者 20 只眼，平均年龄为 48.9 ± 9.40 岁。激光治疗前平均视力为 0.24 ± 0.28 logMAR，激光治疗后 3 个月时为 0.19 ± 0.25 logMAR，激光治疗后 6 个月时为 0.18 ± 0.27 logMAR。治疗前后视力有统计学差异（p = 0.0001）。激光治疗前平均中央视网膜厚度为 308.10 ± 95.25 μm，激光治疗后 3 个月时为 233.65 ± 81.17 μm，激光治疗后 6 个月时为 203.88 ± 72.79 μm。视力与疾病持续时间（p = 0.001）、视力与外核层厚度（p = 0.005）以及慢性病例中外核层厚度与疾病持续时间之间存在统计学关系（p = 0.008）。阈下微脉冲激光治疗后，光学相干断层扫描或眼底自发荧光未见视网膜色素上皮或视网膜损伤。视力似乎与慢性 CSC 的疾病持续时间和外核层厚度变化更相关。阈下微脉冲激光治疗似乎对慢性 CSC 有效，同时在疾病早期，即永久性视网膜损伤发生之前，增加了治疗的成功率。
